Jones Trading Rates ProQR Therapeutics (PRQR) buy

Jones Trading reaffirmed its Buy rating on PRQR, setting a $10 target, a 538.98% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 1:02 PM EDT · Updated Jun 27, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Jones Trading rated ProQR Therapeutics N.V. ($PRQR) "buy" with a $10 price target on June 26, 2026.

Since the rating, $PRQR is up 12.4% after 1 week, up 13.1% after 1 month and down 14.4% to date (from the $1.53 close on Jun 26, 2026).

PRQR ProQR Therapeutics N.V.

$1.31 -34.17% year to date

Daily close · Oct 16, 2026

Key Points

On June 26, 2026, Jones Trading reiterated its Buy rating on PRQR, setting a $10 price target.
Jones Trading's $10 price target implies 538.98% upside from ProQR Therapeutics N.V.'s ($PRQR) current $1.56 share price.
PRQR shares traded at $1.56 on Friday, with peers like Adage Capital holding 6.25 million shares.
Insider Hinsch Gylvin Lykke bought 14,495 shares on June 2, 2026, while Chardan Capital also maintains a Buy rating.

Get $PRQR trade alerts by text

We text you when insiders, Congress or big funds trade $PRQR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ProQR Therapeutics N.V. alert may contain errors. Disclosures

Jones Trading, through analyst Catherine Novack, reiterated its Buy rating on PRQR on June 26, 2026. The firm set a price target of $10, showing confidence in the stock's potential. PRQR shares traded at $1.56 on Friday.

Analyst rating track record

Jones Trading vs. the S&P 500

YTD return +57.97% hypothetical

All-time return +164.04% S&P 500 +30.03%

vs. S&P 500 +134.01% ahead of the index

Hypothetical returns from Jones Trading's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in PRQR

Adage Capital Partners GP, L.L.C. held steady with 6,253,467 shares valued at approximately $10.1 million. Privium Fund Management B.V. added 109,387 shares, bringing its total to 5,467,149 shares worth about $8.86 million, marking a 2% increase. Aberdeen Group PLC increased its stake by 366,289 shares to 3,316,965 shares, valued around $5.37 million, reflecting a 12.4% boost. Meanwhile, SIO Capital Management, LLC reduced its holdings by 209,466 shares, ending with 1,954,715 shares worth roughly $3.17 million.

Insider Buying and Selling at ProQR Therapeutics N.V.

On June 2, 2026, insider Hinsch Gylvin Lykke purchased 14,495 shares of PRQR. The transaction was not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 26, 2026, Chardan Capital maintained its Buy rating with a $3 price target, while Jones Trading reiterated a Buy with a $10 target. The consensus among analysts remains positive, with a Buy recommendation and multiple firms setting targets between $3 and $10.

About PRQR

PRQR, operating in the biotechnology sector, focuses on developing innovative treatments for genetic disorders. The company's research and development efforts aim to address unmet medical needs through advanced genetic therapies. With a dedicated team, PRQR strives to bring new solutions to market that can significantly improve patient outcomes.

Bottom Line

Jones Trading's reiterated Buy rating and $10 target for PRQR highlights investor interest in the company's potential. As with all 13F filings and analyst reports, these insights reflect past data and should be considered accordingly. Investors often track such updates for trends and sentiment in the market.

12-month forecast